ARCHIMED completed the acquisition of a 60% stake in ARK Diagnostics from Soulbrain for $257m.

ARCHIMED, a private equity healthcare specialist, completed the acquisition of a 60% stake in ARK Diagnostics, a company specialised in the development and manufacture of specialty immunoassay in vitro diagnostics, from Soulbrain, a specialty chemical company, for $257m. “Combining forces with Soulbrain and working with existing management is a recipe for super-charging ARK’s impressive growth. All of us, Ark, Soulbrain and ARCHIMED, are very comfortable working together after EUROlyser’s success,” Vincent Guillaumot, ARCHIMED Managing Partner.